title: Advances in the pharmacological treatment of gastro-oesophageal cancer.
abstract: Despite a sharp decline in the incidence of gastric cancer during the second half of the 20th century, this malignancy remains the second leading cause of cancer mortality in the world. The incidence and mortality rate of gastric cancer increase with age; at present, the median ages at diagnosis are 67 years for men and 72 years for women in the US. This article reviews and discusses current medical treatment options for both the general population and elderly gastric cancer patients. Management of localized gastric cancer has changed significantly over recent years. Adjuvant chemoradiation is not generally recommended outside the US. After decades of trials of adjuvant chemotherapy with inconclusive results, a significant survival benefit for perioperative combination chemotherapy - as compared with surgery alone - in patients with resectable or locally advanced gastro-oesophageal cancer was recently demonstrated in the UK MAGIC trial. A further large, randomized trial from Japan demonstrated a significant survival benefit for adjuvant chemotherapy with S-1 after D2 resection for gastric cancer. However, both trials are applicable only to the population in which the trials were conducted. Specific data on elderly patients are missing. For patients with metastatic disease, oral fluoropyrimidines, such as capecitabine, have been developed. In Asian patients, treatment with the oral fluoropyrimidine S-1 is safe and effective. Docetaxel, oxaliplatin and irinotecan have demonstrated activity against gastric cancer in appropriately designed, randomized, phase III trials and have increased the available treatment options significantly. In addition, according to preliminary data, trastuzumab in combination with chemotherapy has significantly improved activity when compared to chemotherapy alone in patients with human epidermal receptor (HER)-2-positive gastric and gastro-oesophageal cancers. Thus, therapeutic decisions in patients with advanced gastric cancer may be adapted to the molecular subtype and co-morbidities of the individual patient. Data from retrospective analyses suggest that oxaliplatin seems to be better tolerated than cisplatin in elderly patients.
authors.affiliation: Multidisciplinary Oncology Center, University of Lausanne Hospitals, Lausanne, Switzerland.
authors.forename: Anna Dorothea
authors.initials: AD
authors.lastname: Wagner
authors.forename: Ulrich
authors.initials: U
authors.lastname: Wedding
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D015577:Geriatric Assessment; D006801:Humans; D010166:Palliative Care; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents
references.citation: Am J Clin Oncol. 1999 Dec;22(6):580-6
references.pmid: 10597742
references.citation: Br J Cancer. 2008 Apr 22;98(8):1301-4
references.pmid: 18362933
references.citation: N Engl J Med. 2007 Nov 1;357(18):1810-20
references.pmid: 17978289
references.citation: J Clin Oncol. 2000 Jul;18(14):2648-57
references.pmid: 10894863
references.citation: Hematol Oncol Clin North Am. 2000 Feb;14(1):17-23
references.pmid: 10680069
references.citation: Cancer. 2000 Feb 15;88(4):921-32
references.pmid: 10679663
references.citation: N Engl J Med. 2008 Jan 3;358(1):36-46
references.pmid: 18172173
references.citation: J Clin Oncol. 2004 Nov 1;22(21):4319-28
references.pmid: 15514373
references.citation: Eur J Cancer. 2006 May;42(7):827-34
references.pmid: 16466913
references.citation: J Clin Oncol. 2007 Jun 10;25(17):2490-1; author reply 2491-3
references.pmid: 17557965
references.citation: J Clin Epidemiol. 2003 Jan;56(1):1-9
references.pmid: 12589864
references.citation: N Engl J Med. 2001 Oct 11;345(15):1091-7
references.pmid: 11596588
references.citation: Drugs. 2001;61(15):2309-26
references.pmid: 11772141
references.citation: JAMA. 2001 Jun 6;285(21):2750-6
references.pmid: 11386931
references.citation: Ann Oncol. 2000 Jul;11(7):837-43
references.pmid: 10997811
references.citation: J Pathol. 2007 Jan;211(1):45-51
references.pmid: 17117405
references.citation: Am J Clin Oncol. 2008 Jun;31(3):259-63
references.pmid: 18525305
references.citation: J Chemother. 2007 Feb;19(1):85-9
references.pmid: 17309856
references.citation: Eur J Surg. 2002;168(11):597-608
references.pmid: 12699095
references.citation: Br J Cancer. 2008 Aug 19;99(4):584-90
references.pmid: 18665164
references.citation: Clin Cancer Res. 1999 Jul;5(7):1696-702
references.pmid: 10430071
references.citation: Ann Oncol. 2004 Dec;15(12):1773-81
references.pmid: 15550582
references.citation: Eur J Cancer. 1999 Jul;35(7):1059-64
references.pmid: 10533448
references.citation: J Clin Oncol. 2006 Oct 20;24(30):4922-7
references.pmid: 17050876
references.citation: Crit Rev Oncol Hematol. 2008 Apr;66(1):84-90
references.pmid: 18243012
references.citation: J Clin Oncol. 1998 Apr;16(4):1582-7
references.pmid: 9552069
references.citation: Crit Rev Oncol Hematol. 2005 Sep;55(3):241-52
references.pmid: 16084735
references.citation: BMC Cancer. 2006 May 10;6:125
references.pmid: 16686939
references.citation: Drugs. 2008;68(3):299-317
references.pmid: 18257608
references.citation: Ann Oncol. 2002 Oct;13(10):1568-75
references.pmid: 12377644
references.citation: J Am Geriatr Soc. 1991 Aug;39(8):778-84
references.pmid: 1906492
references.citation: J Clin Oncol. 1997 Jan;15(1):110-5
references.pmid: 8996131
references.citation: J Clin Oncol. 2002 Jan 15;20(2):494-502
references.pmid: 11786579
references.citation: Br J Cancer. 2003 Oct 20;89(8):1428-32
references.pmid: 14562012
references.citation: J Clin Oncol. 2007 Aug 1;25(22):3188-90
references.pmid: 17664464
references.citation: J Clin Oncol. 2003 Apr 1;21(7):1383-9
references.pmid: 12663731
references.citation: Clin Pharmacokinet. 2001;40(2):85-104
references.pmid: 11286326
references.citation: Ann Oncol. 2005 Feb;16(2):273-8
references.pmid: 15668283
references.citation: Br J Surg. 2007 Dec;94(12):1468-76
references.pmid: 17948223
references.citation: Ann Oncol. 2007 Mar;18(3):510-7
references.pmid: 17164226
references.citation: J Clin Oncol. 2003 Jan 1;21(1):54-9
references.pmid: 12506170
references.citation: Crit Rev Oncol Hematol. 2005 May;54(2):129-36
references.pmid: 15843095
references.citation: J Gen Intern Med. 2004 Oct;19(10):1027-33
references.pmid: 15482555
references.citation: Eur J Cancer. 1998 Jul;34(8):1274-81
references.pmid: 9849491
references.citation: Cancer Control. 2007 Jan;14(1):44-56
references.pmid: 17242670
references.citation: Cancer. 2002 May 15;94(10):2766-92
references.pmid: 12173348
references.citation: Ann Oncol. 2008 May;19 Suppl 2:ii23-4
references.pmid: 18456755
references.citation: Cancer. 1995 Mar 15;75(6 Suppl):1418-25
references.pmid: 7889468
references.citation: Ann Surg. 1998 Oct;228(4):449-61
references.pmid: 9790335
references.citation: Crit Rev Oncol Hematol. 2007 May;62(2):164-71
references.pmid: 17169569
references.citation: Ann Surg. 2002 Jul;236(1):37-42
references.pmid: 12131083
references.citation: N Engl J Med. 2001 Sep 6;345(10):725-30
references.pmid: 11547741
references.citation: J Clin Oncol. 2008 Mar 20;26(9):1443-51
references.pmid: 18349394
references.citation: Br J Cancer. 2000 Aug;83(4):458-62
references.pmid: 10945491
references.citation: Ann Oncol. 2008 Aug;19(8):1450-1457
references.pmid: 18558665
references.citation: J Clin Oncol. 2006 Sep 1;24(25):4085-91
references.pmid: 16943526
references.citation: Br J Cancer. 2005 Jun 20;92(12):2122-8
references.pmid: 15942629
references.citation: N Engl J Med. 1984 Dec 27;311(26):1664-70
references.pmid: 6390207
references.citation: Clin Gastroenterol Hepatol. 2003 Nov;1(6):438-45
references.pmid: 15017643
references.citation: N Engl J Med. 2006 Jul 6;355(1):11-20
references.pmid: 16822992
references.citation: J Clin Oncol. 2008 Mar 20;26(9):1435-42
references.pmid: 18349393
references.citation: Eur J Surg Oncol. 2003 Jun;29(5):450-4
references.pmid: 12798750
references.citation: J Clin Oncol. 2006 Nov 20;24(33):5201-6
references.pmid: 17114652
references.citation: Ann Oncol. 2004 Sep;15(9):1330-8
references.pmid: 15319237
references.citation: J Clin Oncol. 2005 Jan 20;23(3):494-501
references.pmid: 15659494
references.citation: JAMA. 2006 Feb 15;295(7):801-8
references.pmid: 16478903
references.citation: Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004064
references.pmid: 15846694
references.citation: J Clin Oncol. 2005 Oct 1;23(28):6957-65
references.pmid: 16145066
references.citation: ANZ J Surg. 2006 Jun;76(6):458-61
references.pmid: 16768768
references.citation: Lancet Oncol. 2008 Mar;9(3):215-21
references.pmid: 18282805
references.citation: Crit Rev Oncol Hematol. 2007 Oct;64(1):1-9
references.pmid: 17613243
references.citation: J Clin Oncol. 2006 Nov 1;24(31):4991-7
references.pmid: 17075117
references.citation: Ann Oncol. 2009 Sep;20(9):1529-1534
references.pmid: 19474114
references.citation: Cancer Chemother Pharmacol. 1999;44(6):453-60
references.pmid: 10550565